OncoGenex Raises Cash For Prostate Cancer Trials
This article was originally published in The Pink Sheet Daily
OncoGenex raises $50 million in cash to support the development of its earlier stage oncology assets.
You may also be interested in...
Plus news on recent financing activity by Aastrom Biosciences, Tarsa Therapeutics, OncoGenex and Medivation.
Teva and OncoGenex announced changes to the Phase III program of their prostate cancer drug custirsen on the heels of positive data from a competitor.